

1 **Title**

2 Potential application of Rapid Antigen Diagnostic Tests for the detection of infectious individuals
3 attending mass gatherings – a simulation study

4

5 **Authors**

6 Conor G. McAloon¹, Darren Dahly², Cathal Walsh³, Patrick Wall⁴, Breda Smyth⁵, Simon More^{1,6}, Conor
7 Teljeur⁷

8

9 ¹School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland

10 ²School of Public Health, University College Cork, Cork, Ireland

11 ³Department of Mathematics and Statistics, University of Limerick, Limerick, Ireland

12 ⁴School of Public Health, Physiotherapy and Sports Science, University College Dublin, Belfield, Dublin 4,
13 Ireland

14 ⁵Department of Public Health, Health Service Executive West, Galway, Ireland

15 ⁶Centre for Veterinary Epidemiology and Risk Analysis, School of Veterinary Medicine, University College
16 Dublin, Belfield, Dublin, Ireland

17 ⁷Health Information and Quality Authority, George's Court, Dublin 7, Ireland

18

19

20 **Abstract**

21 Rapid Antigen Diagnostic Tests (**RADTs**) for the detection of SARS-CoV-2 offer advantages in that they
22 are cheaper and faster than currently used PCR tests but have reduced sensitivity and specificity. One
23 potential application of RADTs is to facilitate gatherings of individuals, through testing of attendees at
24 the point of, or immediately prior to entry at a venue. Understanding the baseline risk in the tested
25 population is of particular importance when evaluating the utility of applying diagnostic tests for
26 screening purposes. We used incidence data to estimate the prevalence of infectious individuals in the
27 community at a particular time point and simulated mass gatherings by sampling from a series of age
28 cohorts. Nine different illustrative scenarios were simulated, small (n=100), medium (n=1000) and large
29 (n=10,000) gatherings each with 3 possible age constructs: mostly younger, mostly older or a gathering
30 with equal numbers from each age cohort. For each scenario, we estimated the prevalence of infectious
31 attendees, then simulated the likely number of positive and negative test results, the proportion of
32 cases detected and the corresponding positive and negative predictive values, and the cost per case
33 identified. Our findings suggest that for each detected individual on a given day, there are likely to be
34 13.8 additional infectious individuals also present in the community. Prevalence of infectious individuals
35 at events was highest with 'mostly younger' attendees (1.00%), followed by homogenous age gatherings
36 (0.55%) and lowest with 'mostly older events' (0.26%). For small events (100 attendees) the expected
37 number of infectious attendees was less than 1 across all age constructs of attendees. For large events
38 (10,000 attendees) the expected number of infectious attendees ranged from 26 (95% confidence
39 intervals 12 to 45) for mostly older events, to almost 100 (95% confidence intervals 46 to 174) infectious
40 attendees for mostly younger attendees. Given rapid changes in SARS-CoV-2 incidence over time, we
41 developed an RShiny app to allow users to run updated simulations for specific events.

42

43 Introduction

44 COVID-19 remains a serious threat to public health in Ireland, despite the notably high uptake of
45 vaccination. It thus seems likely that additional nonpharmacological interventions (NPIs) will be
46 necessary to adequately control COVID-19, at least for the near future. However, we would also hope to
47 avoid the more costly NPIs relied on earlier in the pandemic, such as severe limits on movement and
48 gathering, as well as closure of non-essential businesses, schools, and other valuable activities.

49 In this context, the wider use of rapid antigen diagnostic tests (RADTs) might be useful for helping to
50 control the spread of SARS-CoV-2, and a range of applications have been proposed [1]. The potential
51 value of RADTs follows from the fact that they are less expensive, easier to use, and return results much
52 faster than the diagnostic PCR tests underpinning the Irish COVID-19 surveillance and test-and-trace
53 systems [2]. There is an important trade off however, as RADTs have both lower specificity (Sp) and
54 sensitivity (Se) to the presence of SARS-CoV-2 than PCR diagnostic tests [3], though there is some
55 evidence to suggest that their ability to detect *infectious* cases could be more favourable [4].

56 Importantly, the performance of RADTs varies by manufacturer [5] , and can be strongly influenced by
57 whether the sample is collected by a trained professional vs the person undergoing the test [6], and if
58 the latter, whether the sample is collected is with or without supervision[7], which has knock-on effects
59 for costs. Also, as for any diagnostic test, the performance of RADTs *in practice* will be strongly
60 influenced by prevalence of cases in the tested population. This is because, for a given test sensitivity
61 and specificity, the probability that an individual testing negative is truly uninfected (the negative
62 predictive value, or NPV) will decrease as prevalence increases, while the probability that an individual
63 testing positive is truly infected (the positive predictive value, or PPV) will decrease as prevalence
64 decreases. Given the above, and the fact that the relative costs of false positives vs false negatives are

65 rarely equal, and can change from context to context, it is important that the cost-effectiveness of
66 RADTs be evaluated for each specific use-case.

67 One potential application of RADTs is to facilitate gatherings of individuals that might otherwise be
68 prohibited, through testing of attendees at the point of, or immediately prior to entry at a venue,
69 previously described as “testing to enable”[1]. Their use in this context has been somewhat evaluated in
70 randomized controlled trials involving RADT based screening of live events (e.g. in Spain [8]). However,
71 such evaluations tended to be conducted when the background prevalence of COVID-19 was relatively
72 low, meaning that the trials were not well-powered to detect impact on SARS-CoV-2 transmission.
73 However, it seems unlikely that similar experiments would be allowed to go forward when the
74 background prevalence is high. Consequently, simulation and/or modelling based approaches might be
75 particularly important for evaluating the use of RADTs in this setting.

76 The aims of this study were: 1) to estimate the prevalence of infectious individuals within a series of age
77 cohorts by simulating from incidence data and parameters to describe the likely number of infectious
78 days in the population; 2) To simulate mass gatherings with different age-cohort structures to estimate
79 an overall prevalence of infectious individuals; and, 3) to simulate the application of RADTs to these
80 populations to determine the likely utility of these tests at a population level for such events.

81

82

83

84

85 **Materials and Methods**

86 ***Overall design***

87 With respect to SARS CoV-2, disease occurrence is typically expressed as an incidence reported over a
88 particular time window (e.g. 14-day incidence). However, for the purpose of screening individuals for
89 gatherings, the interest is in the prevalence of infectious individuals at the point in time of the event,
90 rather than the rate at which new infections occur. The prevalence of infectious individuals at any given
91 time point is determined by the incidence of infection as well as the duration of infectiousness for each
92 infected individual. The duration of infectiousness is likely to vary between individuals due to biological
93 variation[9]. In addition, given that public health measures are introduced to identify and limit the ability
94 of infected individuals to transmit the virus, the *number of infectious days in the community* for each
95 infected case will vary depending on whether or not they are detected, at what point in the infectious
96 process they are detected and whether or not they heed public health advice to restrict their
97 movements. Furthermore, some individuals may not present for a test (and are therefore not detected)
98 yet may limit their movements based on self-suspicion. Finally, differences in vaccine use and clinical
99 fraction by age[10] mean that many of these factors, and therefore the anticipated number of infectious
100 days in the community for each infected case, will vary by age cohort.

101 Consequently, we simulated mass gatherings by sampling from a series of age cohorts. For each age
102 cohort we assumed that the population consisted of five mutually exclusive infected categories (Figure
103 1), which differed according to the likely number of infectious days in the community for infected
104 individuals in that category. First, *detected* cases were assumed to consist of three groups: 1) Those that
105 were infected and identified through forward tracing by national contact tracing programmes
106 irrespective of their symptom status (Det_CT); 2) those that *were not* identified by contact tracing and
107 were *symptomatic* (Det_Symp), and 3), those that *were not* identified by contact tracing and were

108 *asymptomatic* (Det_Asymp). In addition, it is also recognised that true number of SARS-CoV-2 infections
109 exceeds those that were detected and documented [11]. We assumed that these undetected cases
110 could be considered to comprise of two groups: undetected asymptomatic (Undet_Asymp) or
111 undetected symptomatic (Undet_Symp) cases.

112 We used data from contact tracing to estimate the proportion of detected cases in each cohort. Then
113 using probability distributions to represent uncertainty and variability in key parameters determining
114 the number of infectious days in the community for each cohort, we simulated the likely prevalence of
115 infectious individuals for a given 14-day incidence within each age cohort. Gatherings were then
116 simulated with different age cohort structures to estimate the overall prevalence of infectious
117 individuals at the event. Finally, using probability distributions to model diagnostic test sensitivity (Se)
118 and specificity (Sp) for RADTs, we simulated the potential outcome of test applications to these
119 populations in terms of the number of true positives and negatives, number of false positives and
120 negatives, positive and negative predictive values and the cost per case identified.

121 For the purpose of this study, incidence data was taken from Irish case data published on 6th August
122 2021 [12]. However, we also developed an R Shiny user interface to allow users to update incidence and
123 proportion of attendees from each age cohort.

124

125 ***Estimating the proportion of individuals in each 'case category'***

126 The reported case count of SARS-CoV-2 infections reflects the number of individuals in which the virus
127 has been detected. Individuals may be referred for a test due to contact tracing (i.e. after being
128 identified as a close contact of a confirmed case) or for other reasons (e.g., presentation of symptoms,
129 mandatory testing due to travel). In each case, there was a likelihood that the individual may have been

130 infectious for a number of days prior to being test detected. Depending on the circumstances, the
131 individual may or may not have been observing self-isolation or quarantine.

132 Contact tracing has been used in an attempt to interrupt chains of transmission. In Ireland, information
133 on the most likely source, date of last contact and the date of the onset of symptoms are recorded for
134 each individual identified as infected [13]. Using previous data collected from contact tracing data[14],
135 we calculated the proportion of detected cases that were previously identified as contacts as Det_CT.
136 For the remaining detected cases, we calculated the proportions that had symptoms, or those that were
137 asymptomatic at the time of contact tracing as Det_Symp and Det_Asymp respectively.

138 Estimates of the proportion of cases that remain undetected vary across different studies. In reality,
139 changes to the intensity of testing resulting in variation in case ascertainment over time and between
140 regions are likely to impact on these estimates. Mahajan et al. (2021) estimated that 35% of infections
141 were likely detected in the US (data until November 2020) [15], whereas other studies from Europe
142 estimated figures of 40% [11]and 52% [16] from Austria and Italy respectively. In Ireland, three
143 serological studies have been conducted to estimate the proportion of undetected cases, with estimates
144 of the fraction of cases detected ranging from 24-56% [17-19]. Those studies are typically intended to
145 determine the fraction of the population that have developed antibodies indicating exposure to the
146 disease. Frequently those studies also collect information on diagnosed illness of symptoms consistent
147 with the disease. By combining data on sero-prevalence and the diagnostic test accuracy of the antibody
148 tests, the proportion of cases that are undetected can be inferred. For this study, data from the SCOP1
149 study[19] were used in conjunction with a published systematic review of the diagnostic test accuracy of
150 SARS-CoV-2 antibody tests[20] to generate an estimated detected fraction of 50%. We assumed that the
151 majority of these undetected cases were asymptomatic (with no ROM), with the remainder being un-
152 notified/undetected symptomatic cases.

153

154 ***Number of infectious days per infection category***

155 Individuals from each infection category were assumed to have a number of infectious days in the
156 community that was dependent on a number of different factors: point of infection; latent period; pre-
157 symptomatic and symptomatic infectious period for symptomatic individuals, asymptomatic infectious
158 period for asymptomatic individuals; and point at which the individual went into restricted movement
159 (ROM) (Figure 1).

160 For notified cases identified through contact tracing we had information on the estimated number of
161 days from exposure to being requested to restrict movements. Combined with a distribution for the
162 number of days from exposure to becoming infectious (i.e., the latent period), we estimated the
163 distribution for the number of days such an individual was potentially infectious and not restricting their
164 movements.

165 For notified cases not identified through contact tracing, we treated symptomatic and asymptomatic
166 cases separately. For symptomatic cases, we assumed that they would present for testing an average of
167 1 day after symptom onset (95% CI: 0 to 3 days). Thus they would be infectious and not restricting
168 movements for the pre-symptomatic phase and part of the symptomatic phase. For asymptomatic
169 cases, we conservatively assumed that they would be test detected at a random point after the
170 equivalent of the pre-symptomatic infectious period.

171 For all notified cases it was assumed that some portion would not adhere to restriction of movements or
172 self-isolation. Compliance with public health guidance on restriction of movement and self-isolation was
173 assumed to be 90% in close contacts and test detected asymptomatic individuals, and 95% in test
174 detected symptomatic individuals.

175 For undetected cases, it was assumed that asymptomatic cases would not restrict their movements at
176 any point. For undetected symptomatic cases, it was assumed that they would begin to restrict
177 movements at a random point after symptom onset and prior to resolution of symptoms.

178 *Det_CCT*

179 The number of infectious days in the population for each case in the *Det_CCT* category was the period
180 from the end of the latent period up to the point at which the contact tracing phone call was carried out
181 to inform them they were a close contact of a confirmed case. For infected individuals in this category,
182 the time delay was drawn from a distribution fitted to the data of the duration between the last contact
183 with a confirmed case from the Irish national contact tracing data, and the time that CCT were in touch
184 with the contact to inform them of their close contact status. These individuals were assumed to restrict
185 their movements from that period forward and therefore not having further infectious days in the
186 population (Figure 2).

187 *Det_Symp*

188 For those individuals who were symptomatic and detected, they were assumed to restrict their
189 movements shortly after the onset of symptoms. The number of infectious days for this cohort was
190 therefore assumed to be equal to the pre-symptomatic infectious period plus a short duration after the
191 onset of symptoms. For each individual in this cohort, this was simulated using a distribution with a
192 mean of 1 day and a range from 0 to 3 days.

193 *Det_Asymp*

194 Individuals that were detected and asymptomatic were assumed to restrict their movements at some
195 point during the infectious period window. These individuals therefore had a number of infectious days

196 that was between 0-100% of the total potential infectious period duration, for each individual in the
197 simulation, this proportion was drawn from a uniform distribution from 0-1.

198 *Undet_Symp*

199 Undetected symptomatics were assumed to restrict their movements at some random point after the
200 onset of symptoms. For an individual in this category, they were assumed to have a number of
201 infectious days that was equal to the pre-symptomatic infectious duration plus some fraction of the
202 post-symptomatic infectious period duration. For each individual in this cohort in the simulation, this
203 proportion was drawn from a uniform distribution from 0-1.

204 *Undet_Asymp*

205 Those individuals who were undetected and asymptomatic were assumed not to restrict their
206 movement. They were therefore infectious for the total duration of the asymptomatic infectious period.
207 For asymptomatic individuals, the duration of the asymptomatic period was assumed to be the same as
208 the total duration of the infectious period for symptomatic individuals (i.e. the total of the pre and post
209 symptomatic infectious periods).

210 The distributions used to simulate aspects of the infectious process and number of days infectious are
211 shown in Table 1.

212

213 **Table 1.**

Parameter	Mean	2.5th – 97.5 th percentile	Distribution (parameter 1, parameter 2)	Source
Latent period	3.7	1.3 to 8.3	lognormal (1.2, 0.464)	[21, 22]
Pre-symptomatic infectious period	2.4	0.4 to 7.9	lognormal (0.59, 0.75)	[22, 23]

Post-symptomatic infectious period	7.1	2.8 to 11.5	Weibull (3.49, 7.90)	[23, 24]
Delay from exposure to contact trace	5.5	1.0 to 12.0	Sampled from observed distribution	Distribution from Irish contact tracing
RADT Se	0.525*	0.437 to 0.611	Beta (65.31, 59.18)	[25]
RADT Sp	0.999*	0.990 to 1.000	Beta (456.67, 1.46)	[25, 26]

214 *Mode

215 ***Scenario simulation – estimating the number of infectious individuals per event***

216 We simulated a number of different gathering events. We used 3 different event gathering sizes: 100
217 individuals, 1,000 individuals and 10,000 individuals. For each, we simulated 3 different age cohorts: 1,
218 ‘Homogenous population’ where equal numbers were drawn from all age cohorts; 2, ‘Mostly younger’
219 events where 50% of attendees were in the 18-24 years age group, 25% were from 0-18 age group, 25%
220 were from 25-39 age group with no attendees older than 40; ‘Mostly older’ age events where the
221 majority (50%) of attendees were in the 40-65+ age group, 25% were from the 25-39 age group, 25%
222 were older than 65 with no attendees aged 39 or younger.

223 Using reported incidence, we partitioned cases into each of the categories in Figure 1, and based on the
224 variables in Table 1, created a probability density function for the prevalence within each age cohort.

225 Next, according to size and age makeup of the event, we drew from each of these distributions to
226 generate an overall number of infectious attendees for each scenario, on each iteration. This process
227 was repeated for 10,000 iterations to capture uncertainty and variability in each of the input
228 parameters.

229

230 ***RADT characteristics***

231 The anticipated number of true positives, false positives, true negatives and false negatives was then
232 calculated by simulating from distributions of sensitivity and specificity of the RADTs. Estimates of the
233 sensitivity and specificity of RADTs for the detection of SARS-CoV-2 infection vary considerably [5, 25].
234 Much of this variation may be attributed to differences in the definition of the target condition. For
235 example in a large screening study in the UK, the reported test sensitivity changed from 0.40 to 0.91
236 when the target condition was changed from PCR positive, to PCR positive with a cycle threshold less
237 than 18.3[27].

238 For the purpose of this study, we assumed that the majority of cases would be asymptomatic and
239 therefore used the asymptomatic subgroup meta-analysis from Brümmer et al. (2021). The sensitivity of
240 the RADT was therefore simulated using a beta distribution with mode of 0.525 and lower 2.5th
241 percentile bound of 0.437[25]. This estimate is similar to a recent report from the use of RADTs in food
242 processing workers in Ireland[26].

243 Brümmer et al. (2021) reported specificity of RADTs greater than 0.990 across different subgroup
244 analyses[25]. In contrast, a recent study of supervised sampling of asymptomatic individuals in meat
245 processing plants in Ireland reported only 2 false positive results from 5032 samples (0.9996). For the
246 purpose of this study, specificity was simulated using a Beta distribution with a mode of 0.999 and a
247 lower bound 0.990.

248 To facilitate modification of the proportions of individuals attending the event, we developed an RShiny
249 application allowing decision makers to specify the number of individuals attending the event, the
250 current or likely incidence per age group, the proportion of attendees from each age cohort and to
251 evaluate the impact on the likely number of infectious attendees, number of true and false, positives
252 and negatives.

253 **Results**

254 Results of the simulation are shown in Table 2. Given the differences in incidence by age group,
255 prevalence of infectious individuals at events was highest with ‘mostly younger’ attendees (1.00%),
256 followed by homogenous age gatherings (0.55%) and lowest with ‘mostly older events’ (0.26%).
257 Consequently, the positive predictive value was lowest in the older aged events (0.39, 95% confidence
258 intervals 0.10, 0.86), and was highest in the younger aged events (0.66, 95% confidence intervals 0.29,
259 0.96). As an example, Figure 2 shows the difference in numbers of true and false positive and negatives
260 across two illustrative scenarios.

261 For small events (100 attendees) the expected number of infectious attendees was less than or equal to
262 1 across all age constructs of attendees. For mostly younger events the expected number of infectious
263 attendees was 1.0 and the 95th percentile was 4, whereas for mostly older events the expected number
264 of infectious attendees was 0.26 with a 95th percentile of 2. For large events (10,000 attendees) the
265 expected number of infectious attendees ranged from 26 (95% confidence intervals 12 to 45) for mostly
266 older events, to almost 100 (95% confidence intervals 46 to 174) infectious attendees for mostly
267 younger attendees.

268 Given the characteristics of the test, approximately half of these individuals were likely to be detected
269 with the remainder being false negatives. However, there was significant variation with the number of
270 false negatives ranging from 0, 1 for small gatherings of mostly older individuals, to 20 to 86 false
271 negatives at a large gathering of mostly younger individuals.

272 For homogenous population events the expected number of false positive attendees was 0.3, 1.6 and
273 31.3 for small, medium, and large events respectively. However, there was also significant variation with
274 this value, with 95% confidence intervals ranging from 0 to 2 for small gatherings of mostly younger
275 attendees, to between 2 and 101 for large gatherings of mostly older individuals.

276

Congregation scenario	Prevalence	Positive predictive value	Event size	Mean number of infected attendees (95% confidence intervals)	Mean number of true positives (95% confidence intervals)	Mean number of false positives (95% confidence intervals)	Mean number of true negatives (95% confidence intervals)	Mean number of false negatives (95% confidence intervals)
Homogenous population	0.0055 (0.0033, 0.0083)	0.5457 (0.2007, 0.9317)	100	0.54 (0, 2)	0.28 (0, 2)	0.32 (0, 2)	99.13 (97, 100)	0.26 (0, 2)
			500	2.77 (0, 7)	1.45 (0, 4)	1.56 (0, 6)	495.66 (490, 500)	1.32 (0, 6)
			10000	54.95 (30, 88)	28.84 (14, 49)	31.99 (1, 104)	9913.06 (9837, 9958)	26.11 (1, 104)
Mostly younger	0.01 (0.0049,	0.6628 (0.2942,	100	1.01 (0, 4)	0.53 (0, 2)	0.32 (0, 2)	98.67 (96, 100)	0.48 (0, 2)

	0.0171)	0.9613)						
			500	4.99 (1, 11)	2.61 (0, 7)	1.61 (0, 6)	493.4 (486, 499)	2.38 (0, 6)
			10000	99.58 (46, 174)	52.23 (22, 95)	31.3 (1, 100)	9869.12 (9773, 9937)	47.35 (20, 86)
Mostly older	0.0026 (0.0015, 0.0041)	0.391 (0.1049, 0.8647)	100	0.26 (0, 2)	0.14 (0, 1)	0.32 (0, 2)	99.42 (97, 100)	0.12 (0, 2)
			500	1.32 (0, 4)	0.69 (0, 3)	1.56 (0, 6)	497.12 (492, 500)	0.64 (0, 6)
			10000	26.53 (12, 45)	13.92 (5, 26)	31.97 (2, 102.025)	9941.5 (9870, 9978)	12.61 (2, 102.025)

278

279

280

281 Discussion

282 Understanding the baseline risk in the tested population is of particular importance when evaluating the
283 utility of applying of diagnostic tests for screening purposes. In the context of SARS-CoV-2, case
284 incidence rates are constantly changing. Our study used incidence data to estimate the prevalence of
285 infectious individuals in the community at a particular point in time. However, the methodology can be
286 applied at any time, and therefore has potential as a real-time calculation to support decision making
287 about the control measures required to facilitate mass gatherings while the pandemic is ongoing.

288 Our findings suggest that for each detected individual on a given day, there are likely to be 13.8
289 additional infectious individuals also present in the community. This ‘multiplier’ includes individuals who
290 will be detected on subsequent days, as well as asymptomatic individuals who will never be detected.
291 Since undetected asymptomatic individuals do not restrict their movement, they contribute a higher
292 number of infectious days in the community, although these individuals are generally considered to
293 have potentially lower infectiousness than symptomatic individuals[28].

294 To estimate prevalence from incidence data, we assumed that approximately 50% of cases were
295 detected. This figure is consistent with the international and national literature [11, 15-19]. Undetected
296 cases are a function of numerous factors including testing capacity, disease prevalence, practice
297 regarding referral for testing, and asymptomatic disease. In periods of disease surge, testing capacity
298 comes under pressure and tends to be prioritised for symptomatic cases, increasing the proportion
299 undetected. Frontline healthcare workers are generally highly tested because of their increased risk of
300 exposure and to minimise risk too patients, and as such sero-prevalence studies including healthcare
301 workers may under-estimate the undetected fraction. For this analysis, we used an Irish sero-prevalence
302 study that was conducted during June and July 2020.[19] The study may over-estimate of the
303 undetected fraction on the grounds that it includes infections in the early stages of the epidemic when

304 testing capacity in Ireland was low. Modelling studies have since shown that there was significant under-
305 ascertainment of cases particularly at the peak of the first wave across many countries [29]. Two other
306 Irish sero-prevalence studies have been published: one found a lower undetected fraction (38%) but was
307 focused on hospital-based healthcare workers[18] and a second that was based in primary care and
308 found a higher undetected fraction (73%).[17] For this analysis a wide range of uncertainty was adopted
309 for the undetected fraction to reflect the limited data available and the fact that the undetected fraction
310 is likely to vary over time.

311 We estimated that the expected prevalence of infectious attendees attending simulated events ranged
312 from 0.2 – 1.0%. This study demonstrates that the prevalence of infectious individuals attending events
313 are likely to be higher for events comprised of mostly younger age cohorts. It is worth noting that the
314 impact of infection in these individuals is much lower [30], however, given contact rates within and
315 between different age cohorts [31], higher rates of infection in in younger age groups is likely to lead to
316 increased community incidence and ultimately, transmission to older, higher risk age cohorts.

317 Interestingly, our study showed that with older events, the positive predictive value of the test was
318 expected to be less than 40% in all scenarios modelled. Estimates of the specificity of RADT tests are
319 generally very high (in excess of 0.99) [25], however even with ‘higher’ prevalence events made of
320 mostly younger individuals, the absolute prevalence tended to be very low (less than 1%). Given the low
321 prevalence of infectious individuals, the occurrence of false positives although rare, occur at higher
322 frequencies than true positives leading to the low positive predictive value. However, it is worth noting
323 that for this older age cohort, the impact of infection if much higher than for the other age groups
324 simulated[32], therefore a lower positive predictive value might be tolerated.

325 There are many potential applications of RADT as an aid to the control of SARS-CoV-2 control, Crozier
326 (2021) broadly categorised these as 1) focused asymptomatic testing, 2) focused asymptomatic testing

327 including for example testing for early release from quarantine, and testing to enable otherwise
328 restricted activities, and 3) mass testing. The scenarios modelled in the current study represent only one
329 potential application of the test and should not be used as evidence to support or refute the of RADTs in
330 other contexts [1]. Furthermore, a number of limitations are important to note. For the purpose of this
331 study, we used published estimates of the sensitivity and specificity largely informed by a systematic
332 review and meta-analysis [25]. As is the case for many test validation studies, these values are based on
333 the use of the test relative to a gold standard. For these studies, PCR is used as a pseudo gold standard.
334 However, PCR itself should not be considered a gold standard test and likely has a test sensitivity which
335 is less than 100% [33], therefore the true sensitivity of the RADT may be lower than that used for the
336 analysis. It is also recognised, that 'reference test' approaches to diagnostic test evaluation will also
337 likely underestimate the specificity of the evaluated test when the reference test is not a true gold
338 standard [34].

339 On the other hand, a key consideration for such studies is the target condition which the test aims to
340 identify. In our study, we simulated prevalences of *infectious* individuals by considering the duration of
341 the infectious window and likely restriction of movement of infected individuals. However, this target
342 condition does not necessarily align with the sensitivity estimated in conventional test validation studies
343 which conventionally will include individuals who are PCR detectable but may not be infectious. It has
344 been shown that sensitivity of RADTs varies according to the Ct-value of the corresponding PCR test
345 [26], with transmissibility increasing at lower Ct-values [35]. Estimates of the sensitivity and specificity of
346 any given test will therefore vary according to the distribution of Ct-values within infected individuals in
347 the sampled population. For this study we did not differentiate between different 'degrees of
348 infectiousness' for example between detected and undetected infected attendees, or between
349 symptomatic and asymptomatic individuals.

350 Our analysis also assumed that individuals within age cohorts were independently drawn at random
351 from the overall population. However, it is likely that some degree of clustering is likely to occur with
352 cases, which was not considered in our study. Clustering of cases could result in a disproportionate
353 number of infectious people present at the event, such that realistic range of numbers of infectious
354 individuals potentially attending an event may be greater than those simulated. However, clustering
355 would also imply that those potentially infectious individuals may stay within their grouping and mix
356 less, and therefore it may not lead to markedly increased transmission.

357 Finally, it is also important to note that the outcomes of the study are conditional on the incidences in a
358 particular region at a particular point in time. In order to facilitate changing underlying incidence, we
359 developed an RShiny app (<https://mcaloon-ucd.shinyapps.io/radts/>), to estimate the likely number of
360 infectious event attendees, the estimated number of true and false positives and negatives, as well as
361 the positive predictive value and the cost per case identified.

362 **Conclusions**

363 Understanding the baseline risk in the tested population is of particular importance when evaluating the
364 utility of applying of diagnostic tests for screening purposes, however incidence data underestimate the
365 risk of infectious individuals at a point in time. This study provides a useful method to estimate the likely
366 number of infectious attendees at a particular event. Whilst the disease characteristics are likely to be
367 similar across countries, contact tracing strategies are likely to change within and between countries
368 over time. However with some adaptations, this method could be easily applied across countries.

369

370 **References**

371 1. Crozier, A., et al., *Put to the test: use of rapid testing technologies for covid-19*. *bmj*, 2021. **372**.

- 372 2. Peeling, R.W., et al., *Scaling up COVID-19 rapid antigen tests: promises and challenges*. The
373 Lancet infectious diseases, 2021.
- 374 3. Osterman, A., et al., *Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital*
375 *setting*. Medical microbiology and immunology, 2021. **210**(1): p. 65-72.
- 376 4. Mina, M.J., et al., *Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health*
377 *responses to COVID-19*. The Lancet, 2021. **397**(10283): p. 1425-1427.
- 378 5. Denkinger, C. *Rapid antigen tests for the detection of SARS-CoV-2 infection*. 2021; Available
379 from: <https://www.klinikum.uni-heidelberg.de/en/diagnostics-global-health>.
- 380 6. Lindner, A.K., et al., *Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with*
381 *self-collected nasal swab versus professional-collected nasopharyngeal swab*. European
382 Respiratory Journal, 2021. **57**(4).
- 383 7. Senok, A., et al., *Saliva as an alternative specimen for molecular COVID-19 testing in community*
384 *settings and population-based screening*. Infection and Drug Resistance, 2020. **13**: p. 3393.
- 385 8. Revollo, B., et al., *Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live*
386 *music event: a randomised controlled trial*. The Lancet Infectious Diseases, 2021. **21**(10): p.
387 1365-1372.
- 388 9. Byrne, A.W., et al., *Inferred duration of infectious period of SARS-CoV-2: rapid scoping review*
389 *and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases*. BMJ
390 open, 2020. **10**(8): p. e039856.
- 391 10. Davies, N.G., et al., *Age-dependent effects in the transmission and control of COVID-19*
392 *epidemics*. Nature medicine, 2020. **26**(8): p. 1205-1211.
- 393 11. Rippinger, C., et al., *Evaluation of undetected cases during the COVID-19 epidemic in Austria*.
394 BMC Infectious Diseases, 2021. **21**(1): p. 70.
- 395 12. Centre, H.P.S. *COVID-19 14-day epidemiology reports - August 2021*. 2021 [9th August 2021];
396 Available from: [https://www.hpsc.ie/a-](https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/surveillance/covid-1914-dayepidemiologyreports/)
397 [z/respiratory/coronavirus/novelcoronavirus/surveillance/covid-1914-dayepidemiologyreports/](https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/surveillance/covid-1914-dayepidemiologyreports/).
- 398 13. Carroll, C., et al., *Routine testing of close contacts of confirmed COVID-19 cases – National*
399 *COVID-19 Contact Management Programme, Ireland, May to August 2020*. Public Health, 2021.
400 **190**: p. 147-151.
- 401 14. McAloon, C.G., et al., *Numbers of close contacts of individuals infected with SARS-CoV-2 and*
402 *their association with government intervention strategies*. medRxiv, 2021: p.
403 2021.01.20.21250109.
- 404 15. Mahajan, A., R. Solanki, and N. Sivadas, *Estimation of undetected symptomatic and*
405 *asymptomatic cases of COVID-19 infection and prediction of its spread in the USA*. Journal of
406 medical virology, 2021. **93**(5): p. 3202-3210.
- 407 16. Melis, M. and R. Littera, *Undetected infectives in the Covid-19 pandemic*. International Journal of
408 Infectious Diseases, 2021. **104**: p. 262-268.
- 409 17. O'Callaghan, M.E., et al., *SARS-CoV-2 infection in general practice in Ireland: a seroprevalence*
410 *study*. BJGP Open, 2021. **5**(4).
- 411 18. Allen, N., et al., *Prevalence of antibodies to SARS-CoV-2 in Irish hospital healthcare workers*.
412 Epidemiology and Infection, 2021. **149**: p. e157.
- 413 19. Laboratory, H.S.E.H.P.S.C.a.U.C.D.N.V.R., *Preliminary report of the results of the Study to*
414 *Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A national seroprevalence*
415 *study, June-July 2020*. 2020.
- 416 20. Deeks, J.J., et al., *Antibody tests for identification of current and past infection with SARS-CoV-2*.
417 Cochrane Database of Systematic Reviews, 2020(6).
- 418 21. Authority, H.I.Q., *Evidence summary for the incubation period of COVID-19, or time to first*
419 *positive test, in individuals exposed to SARS-CoV-2*. 2020.

- 420 22. Quilty, B.J., et al., *Quarantine and testing strategies in contact tracing for SARS-CoV-2: a*
421 *modelling study*. The Lancet Public Health, 2021. **6**(3): p. e175-e183.
- 422 23. Walsh, K.A., et al., *The duration of infectiousness of individuals infected with SARS-CoV-2*. Journal
423 of Infection, 2020. **81**(6): p. 847-856.
- 424 24. Singanayagam, A., et al., *Duration of infectiousness and correlation with RT-PCR cycle threshold*
425 *values in cases of COVID-19, England, January to May 2020*. Eurosurveillance, 2020. **25**(32): p.
426 2001483.
- 427 25. Bruemmer, L.E., et al., *The accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living*
428 *systematic review and meta-analysis*. medRxiv, 2021.
- 429 26. Group, H.C.-A.T.W., 2021.
- 430 27. García-Fiñana, M., et al., *Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in*
431 *the Liverpool asymptomatic testing pilot: population based cohort study*. bmj, 2021. **374**.
- 432 28. McEvoy, D., et al., *Relative infectiousness of asymptomatic SARS-CoV-2 infected persons*
433 *compared with symptomatic individuals: a rapid scoping review*. BMJ Open, 2021. **11**(5): p.
434 e042354.
- 435 29. Russell, T.W., et al., *Reconstructing the early global dynamics of under-ascertained COVID-19*
436 *cases and infections*. BMC Medicine, 2020. **18**(1): p. 332.
- 437 30. Turke, P.W., *Five reasons COVID-19 is less severe in younger age-groups*. Evolution, Medicine,
438 and Public Health, 2020. **9**(1): p. 113-117.
- 439 31. McAloon, C.G., et al., *Numbers of close contacts of individuals infected with SARS-CoV-2 and*
440 *their association with government intervention strategies*. BMC Public Health, 2021. **21**(1): p.
441 2238.
- 442 32. Banerjee, A., et al., *Estimating excess 1-year mortality associated with the COVID-19 pandemic*
443 *according to underlying conditions and age: a population-based cohort study*. The Lancet, 2020.
444 **395**(10238): p. 1715-1725.
- 445 33. Moretti, M., et al., *Diagnostic accuracy of screening tests for patients suspected of COVID-19, a*
446 *retrospective cohort study*. Infectious Diseases, 2021. **53**(11): p. 855-864.
- 447 34. Nérette, P., et al., *Using pseudogold standards and latent-class analysis in combination to*
448 *evaluate the accuracy of three diagnostic tests*. Preventive Veterinary Medicine, 2008. **85**(3): p.
449 207-225.
- 450 35. Lyngse, F.P., et al., *Association between SARS-CoV-2 Transmissibility, Viral Load, and Age in*
451 *Households*. medRxiv, 2021: p. 2021.02.28.21252608.

453

454 **Figure 1. Impact of point of detection for each case category on the number of infectious days in the**
455 **community.**

456 **Figure 2. Differences in true and false positives and negatives using two illustrative scenarios.**


Det_CCT
CCT detected cases

Det_Symp
Detected symptomatic cases

Det_Asymp
Detected asymptomatic cases

Undet_Symp
Undetected symptomatic cases

Undet_Asymp
Undetected asymptomatic cases



- Point of infection
- Start of infectiousness
- Onset of symptoms
- End of infectiousness

- Latent period
- Infectious period
- ROM Restriction of Movement
- vROM Voluntary Restriction of Movement

